Panion Animal Health AB (Publ):First trading day for series 2019 warrants
Panion Animal Health AB today announced that the first trading day of warrants of series 2019 will be July 12, 2018. One (1) warrant entitles the holder to subscribe for one (1) new share in the company at a subscription price of SEK 1.31 per share. Subscription of shares under the warrants shall be in accordance with the terms of the warrants during the period from September 1, 2019 through September 30, 2019.
Shares and share capital
The preferential share issue of units has been partly registered at the Swedish Companies Registration Office and the total number of shares amounts to 20 748 042 giving a share capital of SEK 966 939,224775.
Name: Panion Animal Health AB TO 2019
Short name: PANION TO 2
First day of trading: 12 July 2018
Last day of trading: 26 September 2019 Outstanding warrants of series 2019: 4 531 312
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.
Panion Animal Health AB:s (publ) nyemission är nu delregistrerad hos Bolagsverket
Panion Animal Health AB develops a unique gene therapy treatment for dogs with idiopathic epilepsy. A safety study in dogs is currently running at the University of Copenhagen under the lead of Associate Professor David Woldbye, Department of Neuroscience, KU. Preliminary results from the study were expected in Q2, but due to circumstances outside Panion's influence, Panion has just been informed that this timing has been slightly delayed into Q3.
The progress and plans for Panion's development of the gene therapy treatment for dogs with epilepsy, and for Panion's business idea and vision, was presented by Anja Holm, CEO of Panion, at the InvestorDagen event in Århus, Denmark on the 12.th of June.
Panion Animal Health AB is a Swedish registered company with shares on Spotlight/AktieTorget and with a unique product in development - a gene therapy treatment for epilepsy in dogs. We have a strong Scandinavian cooperation in that half of Panion's management and board resides in Denmark. A safety study in dogs is currently running in Denmark in cooperation with the University of Copenhagen and under the lead of Associate professor David Woldbye, Department of neuroscience, KU.
Panion Animal Health AB:s (publ) ("Panion") nyemission av units tecknades till cirka 56 procent och Panion tillförs därigenom en emissionslikvid om cirka 5,2 miljoner kronor före avdrag för emissionskostnader.
Igår, den 29 maj 2018, hölls årsstämma i Panion Animal Health AB. Nedan följer en sammanfattning av de beslut som fattades vid årsstämman.
Board and management members of Panion Animal Health AB (publ), subscribes for shares in the current emission
Panion Animal Health AB ("Panion") is currently offering existing shareholders and others the rights to subscribe for shares in the emission running from 16 - 30 May 2018. The Board of Panion has decided the issue with preference for existing shareholders of a total of approximately SEK 9.2 million.
Panion Animal Health AB
Interim Report Q1 2018
2018-08-22 Delårsrapport Q2 2018